JP2018193386A5 - - Google Patents

Download PDF

Info

Publication number
JP2018193386A5
JP2018193386A5 JP2018137861A JP2018137861A JP2018193386A5 JP 2018193386 A5 JP2018193386 A5 JP 2018193386A5 JP 2018137861 A JP2018137861 A JP 2018137861A JP 2018137861 A JP2018137861 A JP 2018137861A JP 2018193386 A5 JP2018193386 A5 JP 2018193386A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
possessed
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018137861A
Other languages
English (en)
Japanese (ja)
Other versions
JP7012360B2 (ja
JP2018193386A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018193386A publication Critical patent/JP2018193386A/ja
Publication of JP2018193386A5 publication Critical patent/JP2018193386A5/ja
Application granted granted Critical
Publication of JP7012360B2 publication Critical patent/JP7012360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018137861A 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体 Active JP7012360B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013039625 2013-02-28
JP2013039625 2013-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015503025A Division JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体

Publications (3)

Publication Number Publication Date
JP2018193386A JP2018193386A (ja) 2018-12-06
JP2018193386A5 true JP2018193386A5 (enExample) 2019-03-14
JP7012360B2 JP7012360B2 (ja) 2022-02-14

Family

ID=51428352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503025A Active JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体
JP2018137861A Active JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015503025A Active JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体

Country Status (5)

Country Link
US (1) US9429584B2 (enExample)
EP (2) EP2963059B1 (enExample)
JP (2) JP6490574B2 (enExample)
ES (1) ES2673583T3 (enExample)
WO (1) WO2014133093A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167227A1 (ja) * 2015-04-13 2016-10-20 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
JP2018527350A (ja) 2015-09-01 2018-09-20 イミュンワーク インク.Immunwork Inc. 血餅形成の予防及び/又は血栓症の治療のための分子構築物
UA126388C2 (uk) 2016-11-18 2022-09-28 Астеллас Фарма Інк. Fab-фрагмент антитіла до muc1 людини
AU2017367734B2 (en) * 2016-12-01 2025-01-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
SG11201910113PA (en) * 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
BR112020001360A2 (pt) 2017-07-24 2020-08-11 Regeneron Pharmaceuticals, Inc. anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto.
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトMUC1抗体Fabフラグメント、ペプチドリンカー及び/又は配位子を含む複合体
JP2022501428A (ja) * 2018-09-17 2022-01-06 アイカーン スクール オブ メディスン アット マウント シナイ 抗lilrb2抗体およびその使用の方法
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
US12509507B2 (en) 2020-03-31 2025-12-30 National Cancer Center Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein
CA3178880A1 (en) * 2020-03-31 2021-10-07 National Cancer Center Fibrin-binding antibody and pharmaceutical composition containing antibody
EP3916009B1 (en) * 2020-05-26 2023-06-28 Sartorius Lab Instruments GmbH & Co. KG Recombinant proteins based on fibrinogen
WO2023195535A1 (ja) 2022-04-08 2023-10-12 株式会社凜研究所 フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤
CN118240085B (zh) * 2022-10-08 2025-05-09 东莞市朋志生物科技有限公司 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH11206387A (ja) 1991-08-28 1999-08-03 Genpharm Internatl Inc 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
JPH11505107A (ja) 1995-04-28 1999-05-18 アブジェニックス インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
JPH08301900A (ja) 1995-04-28 1996-11-19 Shima Kenkyusho:Kk 可溶性フィブリン複合体に対するモノクローナル抗体
JPH09104700A (ja) 1995-10-09 1997-04-22 Bio Rinkusu Kk 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法
JP2001354700A (ja) 2000-06-12 2001-12-25 Bio Links Kk モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
WO2003000736A1 (en) 2001-06-26 2003-01-03 Agen Biomedical Limited Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin
CA2594289A1 (en) 2004-12-28 2006-07-06 Daiichi Pure Chemicals Co., Ltd. Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
JP5222521B2 (ja) 2004-12-28 2013-06-26 積水メディカル株式会社 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法
KR101591206B1 (ko) * 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
CA2642848C (en) * 2006-03-03 2016-07-12 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
JP5013378B2 (ja) 2007-02-05 2012-08-29 国立大学法人大阪大学 新規ヘキサトリエン−β−カルボニル化合物
EP2359852A4 (en) 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
JP5805363B2 (ja) * 2009-06-26 2015-11-04 和興フィルタテクノロジー株式会社 可溶性凝集体、免疫寛容誘導剤及びその製造方法
JP2012000072A (ja) 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo

Similar Documents

Publication Publication Date Title
JP2018193386A5 (enExample)
JP2020022464A5 (enExample)
JP2019110906A5 (enExample)
JP2024020298A5 (enExample)
JP2017176174A5 (enExample)
JP2020513786A5 (enExample)
CN113316591A (zh) Cd73抗体及其制备方法和应用
JP2019107018A5 (enExample)
JP2017113019A5 (enExample)
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2017523786A5 (enExample)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2013545734A5 (enExample)
JP2018508483A5 (enExample)
JP2018198596A5 (enExample)
JP2016116536A5 (enExample)
MY208649A (en) Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
JP2010506596A5 (enExample)
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
JP2018537962A5 (enExample)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2017500018A5 (enExample)
RU2020142534A (ru) Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство
JP2014111644A5 (enExample)